Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The Coronavirus (COVID 19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sector, which is majorly impacted by the COVID-19 pandemic. The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced disturbances, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, contract research organizations, and other organizations that support drug development shifted to remote working environments. Recently, the U.S. Food and Drug Administration (FDA) guidance (March 2020 and updated on July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits or include novel ways for conducting clinical trials in place of current protocols. Therefore, there are now more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other non-traditional approaches that do not involve in-person visits.
Sciatica Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients